This Jynneos market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historical period can be attributed to the rising threat of emerging infectious diseases, increased government funding for vaccination programs, a rise in international travel, growing public health campaigns, and improvements in the vaccine supply chain.
Growth during the market's forecast period is driven by a shift towards infection prevention, personalized medicine, an increased focus on health system preparedness for infectious diseases, investments in vaccine production and distribution infrastructure, and a rise in immunocompromised individuals. Key trends expected in the forecast period include advancements in treatments, mRNA vaccine technology, the use of AI in vaccine development, advanced adjuvant systems, and innovative formulations.
The growing prevalence of monkeypox cases is expected to drive the growth of the jynneos market in the future. Monkeypox is a viral disease caused by the monkeypox virus, a member of the orthopoxvirus family. The increase in monkeypox cases is largely due to higher global travel and more frequent interactions between wildlife and humans, which facilitate the rapid spread of infectious agents, leading to outbreaks. Jynneos is particularly effective in preventing monkeypox in at-risk individuals and is considered safer for people with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control (ECDC), a Europe-based government agency, reported over 100,000 confirmed monkeypox cases and more than 200 deaths globally from January 2022 to July 2024, with cases spanning over 120 countries. Additionally, from January to April 2022, there were 1,152 suspected monkeypox cases and 55 deaths, with a case fatality rate of 4.8%, reported across 54 health zones in 14 provinces, according to the ECDC. Therefore, the rising number of monkeypox cases is fueling the growth of the jynneos market.
A key trend in the jynneos market is the focus on developing combined vaccines that target multiple diseases at once. Combined vaccines offer protection against several diseases with a single shot, reducing the number of injections needed for full immunization. For instance, in August 2024, Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore's Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) for the prevention of smallpox and monkeypox in adults aged 18 and older at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine designed to be a safer alternative for individuals, including those with compromised immune systems. It was developed to enhance public health preparedness and address emerging infectious diseases.
In May 2024, Bavarian Nordic A/S partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine for children in Africa. This partnership aims to ensure the safety and efficacy of the vaccine in endemic regions and supports the regulatory approval process for its use in children. CEPI is a Norway-based non-profit organization dedicated to accelerating the development of vaccines and biologic countermeasures for epidemic and pandemic threats.
The key company operating in the jynneos market is Bavarian Nordic A/S.
North America was the largest region in the jynneos market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in jynneos report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jynneos market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jynneos is a vaccine designed to provide protection against both monkeypox and smallpox. It contains a modified, non-replicating vaccinia virus, which is similar to the virus used in traditional smallpox vaccines but does not replicate within the body. The immune response generated helps the body recognize and combat monkeypox and smallpox viruses if exposed in the future, offering long-term protection.
The primary indications for jynneos are the prevention of monkeypox and smallpox. Preventing monkeypox involves using the Jynneos vaccine to safeguard high-risk individuals from the virus, which can be transmitted through close contact or animals. Jynneos is available in various formulations, including an injectable form and lyophilized powder for reconstitution. It is distributed through multiple channels such as direct sales, wholesalers, retail pharmacies, and online pharmacies, and is utilized by various end users, including hospitals, specialty clinics, public health organizations, and home healthcare providers.
The jynneos market research report is one of a series of new reports that provides jynneos market statistics, including the jynneos industry global market size, regional shares, competitors with the jynneos market share, detailed jynneos market segments, market trends, and opportunities, and any further data you may need to thrive in the jynneos industry. This jynneos market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jynneos market consists of sales of jynneos vaccine vials (multi-dose) and jynneos vaccine pre-filled auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historical period can be attributed to the rising threat of emerging infectious diseases, increased government funding for vaccination programs, a rise in international travel, growing public health campaigns, and improvements in the vaccine supply chain.
Growth during the market's forecast period is driven by a shift towards infection prevention, personalized medicine, an increased focus on health system preparedness for infectious diseases, investments in vaccine production and distribution infrastructure, and a rise in immunocompromised individuals. Key trends expected in the forecast period include advancements in treatments, mRNA vaccine technology, the use of AI in vaccine development, advanced adjuvant systems, and innovative formulations.
The growing prevalence of monkeypox cases is expected to drive the growth of the jynneos market in the future. Monkeypox is a viral disease caused by the monkeypox virus, a member of the orthopoxvirus family. The increase in monkeypox cases is largely due to higher global travel and more frequent interactions between wildlife and humans, which facilitate the rapid spread of infectious agents, leading to outbreaks. Jynneos is particularly effective in preventing monkeypox in at-risk individuals and is considered safer for people with weakened immune systems compared to traditional smallpox vaccines. For example, in September 2024, the European Centre for Disease Prevention and Control (ECDC), a Europe-based government agency, reported over 100,000 confirmed monkeypox cases and more than 200 deaths globally from January 2022 to July 2024, with cases spanning over 120 countries. Additionally, from January to April 2022, there were 1,152 suspected monkeypox cases and 55 deaths, with a case fatality rate of 4.8%, reported across 54 health zones in 14 provinces, according to the ECDC. Therefore, the rising number of monkeypox cases is fueling the growth of the jynneos market.
A key trend in the jynneos market is the focus on developing combined vaccines that target multiple diseases at once. Combined vaccines offer protection against several diseases with a single shot, reducing the number of injections needed for full immunization. For instance, in August 2024, Bavarian Nordic A/S, a Denmark-based biotechnology company, announced that Singapore's Health Sciences Authority (HSA) had approved JYNNEOS (MVA-BN) for the prevention of smallpox and monkeypox in adults aged 18 and older at high risk for these infections. JYNNEOS (MVA-BN) is a non-replicating vaccine designed to be a safer alternative for individuals, including those with compromised immune systems. It was developed to enhance public health preparedness and address emerging infectious diseases.
In May 2024, Bavarian Nordic A/S partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine for children in Africa. This partnership aims to ensure the safety and efficacy of the vaccine in endemic regions and supports the regulatory approval process for its use in children. CEPI is a Norway-based non-profit organization dedicated to accelerating the development of vaccines and biologic countermeasures for epidemic and pandemic threats.
The key company operating in the jynneos market is Bavarian Nordic A/S.
North America was the largest region in the jynneos market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in jynneos report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jynneos market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Jynneos is a vaccine designed to provide protection against both monkeypox and smallpox. It contains a modified, non-replicating vaccinia virus, which is similar to the virus used in traditional smallpox vaccines but does not replicate within the body. The immune response generated helps the body recognize and combat monkeypox and smallpox viruses if exposed in the future, offering long-term protection.
The primary indications for jynneos are the prevention of monkeypox and smallpox. Preventing monkeypox involves using the Jynneos vaccine to safeguard high-risk individuals from the virus, which can be transmitted through close contact or animals. Jynneos is available in various formulations, including an injectable form and lyophilized powder for reconstitution. It is distributed through multiple channels such as direct sales, wholesalers, retail pharmacies, and online pharmacies, and is utilized by various end users, including hospitals, specialty clinics, public health organizations, and home healthcare providers.
The jynneos market research report is one of a series of new reports that provides jynneos market statistics, including the jynneos industry global market size, regional shares, competitors with the jynneos market share, detailed jynneos market segments, market trends, and opportunities, and any further data you may need to thrive in the jynneos industry. This jynneos market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The jynneos market consists of sales of jynneos vaccine vials (multi-dose) and jynneos vaccine pre-filled auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Jynneos Market Characteristics4. Jynneos Market Trends and Strategies5. Jynneos Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Jynneos Pricing Analysis & Forecasts30. Global Jynneos Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Jynneos Market32. Recent Developments in the Jynneos Market
3. Jynneos Market Biologic Drug Characteristics
6. Global Jynneos Growth Analysis and Strategic Analysis Framework
8. Jynneos Market Segmentation
9. Global Jynneos Epidemiology of Clinical Indications
10. Jynneos Market Regional and Country Analysis
11. Asia-Pacific Jynneos Market
12. China Jynneos Market
13. India Jynneos Market
14. Japan Jynneos Market
15. Australia Jynneos Market
16. South Korea Jynneos Market
17. Western Europe Jynneos Market
18. UK Jynneos Market
19. Germany Jynneos Market
20. France Jynneos Market
21. Eastern Europe Jynneos Market
22. North America Jynneos Market
23. USA Jynneos Market
24. Canada Jynneos Market
25. South America Jynneos Market
26. Middle East Jynneos Market
27. Africa Jynneos Market
28. Jynneos Market Competitive Landscape and Company Profiles
29. Global Jynneos Market Pipeline Analysis
33. Jynneos Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Jynneos Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on jynneos market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for jynneos? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The jynneos market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Prevention of Monkeypox; Prevention of Smallpox2) by Formulation: Injectable Formulation; Lyophilized Powder for Reconstitution
3) by Patient Demographics: Adult Patients; Pediatric Patients; High-Risk Populations
4) by Distribution channel: Direct Sales; Wholesalers and Distributors; Retail Pharmacies; Online Pharmacies
5) by End User: Hospitals; Specialty Clinics; Public Health Organizations; Home Healthcare Providers
Key Companies Mentioned: Bavarian Nordic a/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Bavarian Nordic A/S
